Business Context and Reporting Period
This Form 8-K Current Report for IMMUNIC, INC. (Nasdaq: IMUX) covers events occurring on or around August 6, 2026. The filing primarily addresses significant changes in corporate governance and executive leadership, alongside a reference to the Company's financial results for the quarter ended June 30, 2026, which were announced via a separate press release.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained in the "Earnings Release" (Exhibit 99.1) but are not detailed within the body of this 8-K document.
However, the filing discloses specific financial obligations related to executive separation:
- Severance Lump Sum: $670,000 (representing 12 months of base salary).
- Pro-rated Bonus: $276,375 (75% of the 2026 target bonus).
- Consulting Retainer: €15,000 per month for 12 months.
- Healthcare Reimbursement: Up to €1,500 per month for 18 months.
- Legal Fee Reimbursement: Up to $20,000.
Material Changes
Executive Departure
Dr. Daniel Vitt resigned as a member of the Board of Directors effective August 6, 2026. He had previously resigned as Chief Executive Officer effective June 1, 2026. His employment terminated on August 7, 2026, pursuant to a Separation Agreement.
- Dr. Vitt will serve as Chair of the Scientific Advisory Board (SAB).
- He will act as a consultant to the Company's German subsidiary for 12 months.
- 100% of his outstanding equity awards vested immediately upon separation.
Board Appointment
Elena Ridloff was appointed as a Class I Director effective August 6, 2026. Her term lasts until the 2027 annual meeting.
- Background: Former CFO of Sionna Therapeutics and ACADIA Pharmaceuticals; former Managing Director at Maverick Capital.
- Compensation: Received an inaugural grant of options to purchase 50,740 shares, vesting monthly over three years. She will also receive standard cash compensation for non-employee directors.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or forward-looking outlook statements. The Company refers investors to the August 11, 2026 press release (Exhibit 99.1) for the corporate update and financial results.
Risks and Contingencies:
- Leadership Transition: The Company is navigating the transition following the departure of its former CEO and Board member, Dr. Vitt.
- Legal Obligations: The Company has entered into binding separation and consulting agreements with Dr. Vitt, creating fixed cash outflows over the next 18 months.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 11, 2026) for actual Q2 2026 revenue, net loss, and cash position figures.
- Verify the total cash impact of Dr. Vitt's separation package, including the timing of the $670,000 lump sum and the €15,000 monthly consulting fees.
- Confirm the vesting schedule and exercise price of the 50,740 options granted to new Director Elena Ridloff.
- Assess the strategic implications of Dr. Vitt's continued role as Chair of the Scientific Advisory Board and consultant to the German subsidiary.